对于使用稳定剂量口服抗凝剂的患者，我们推荐凝血功能监测时间间隔不超过4周(2C)。
For patients who are receiving a stable dose of oral anticoagulants, we suggest monitoring at an interval of no longer than every 4 weeks (Grade 2c).
希美加群是一种新型的口服抗凝剂。现就希美加群的药代学和药动学特性以及围绕其进行的一些临床试验进行简单介绍。
Ximelagatran is a new oral anticoagulant. This article introduces the pharmacodynamic and pharmacokinetic properties of ximelagatran and gives a brief description of some relevant clinical trials.
希美加群是一种新型的口服抗凝剂。现就希美加群的药代学和药动学特性以及围绕其进行的一些临床试验进行简单介绍。
Ximelagatran is a new oral anticoagulant. This article introduces the pharmacodynamic and pharmacokinetic properties of ximelagatran and gives a brief description of some relevant clinical trials.
应用推荐